Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age

Vaccine

Volumn 35, Issue 47, 2017, Pages 6355-6358

  Halstead, Scott B ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; DENGVAXIA; NEUTRALIZING ANTIBODY; PLACEBO; LIVE VACCINE;

AGE DISTRIBUTION; ARTICLE; CASE FATALITY RATE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RESPONSE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; INFECTION RATE; NONHUMAN; PREVALENCE; PRIMARY INFECTION; PRIORITY JOURNAL; SECONDARY INFECTION; VACCINATION; VIRUS TRANSMISSION; ADOLESCENT; ADULT; AGE; AGED; ANTIBODY DEPENDENT ENHANCEMENT; CHEMICALLY INDUCED; CHILD; FEMALE; MALE; MIDDLE AGED; PRESCHOOL CHILD; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODY-DEPENDENT ENHANCEMENT; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 85030787378     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.09.089     Document Type: Article

References (26)

1. Gessner, B.D., Halsey, N., Dengue vaccine safety signal: immune enhancement, waning immunity, or chance occurrence?. Vaccine 35 (2017), 3452–3456.
2. Hadinegoro, S.R., Arredondo-Garcia, J.L., Capeding, M.R., Deseda, C., Chotpitayasunondh, T., Dietze, R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373 (2015), 1195–1206.
3. Guy, B., Jackson, N., Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 14 (2016), 45–54.
4. Guzman, M.G., Alvarez, M., Halstead, S.B., Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 158 (2013), 1445–1459.
5. Henein, S., Swanstrom, J., Byers, A.M., Moser, J.M., Shaik, S.F., Bonaparte, M., et al. Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals. J Infect Dis. 215 (2017), 351–358.
6. Capeding, M.R., Tran, N.H., Hadinegoro, S.R., Ismail, H.I., Chotpitayasunondh, T., Chua, M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384 (2014), 1358–1365.
7. Villar, L., Dayan, G.H., Arredondo-Garcia, J.L., Rivera, D.M., Cunha, R., Deseda, C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372 (2014), 113–123.
8. Halstead, S.B., Russell, P.K., Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 34 (2016), 1643–1647.
9. Secretariat. Background paper on dengue vaccines. SAGE working group on dengue vaccine. Geneva: World Health Organization; 2016.
10. Halstead, S.B., Immunological parameters of Togavirus disease syndromes. Schlesinger, R.W., (eds.) The togaviruses, biology, structure, replication, 1980, Academic Press, New York, 107–173.
11. Livingston, P.G., Kurane, I., Dai, L.C., Okamoto, Y., Lai, C.J., Men, R., et al. Dengue virus-specific, HLA-B35-restricted, human CD8(+) cytotoxic T lymphocyte (CTL) clones – recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. JImmunol 154 (1995), 1287–1295.
12. Yauch, L.E., Zellweger, R.M., Kotturi, M.F., Qutubuddin, A., Sidney, J., Peters, B., et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 182 (2009), 4865–4873.
13. Weiskopf, D., Sette, A., T-cell immunity to infection with dengue virus in humans. Front Immunol, 5, 2014, 93.
14. Hatch, S., Endy, T.P., Thomas, S., Mathew, A., Potts, J., Pazoles, P., et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 203 (2011), 1282–1291.
15. Weiskopf, D., Angelo, M.A., de Azeredo, E.L., Sidney, J., Greenbaum, J.A., Fernando, A.N., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 110 (2013), E2046–E2053.
16. Weiskopf, D., Angelo, M.A., Sidney, J., Peters, B., Shresta, S., Sette, A., Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J Virol 88 (2014), 11383–11394.
17. Weiskopf, D., Cerpas, C., Angelo, M.A., Bangs, D.J., Sidney, J., Paul, S., et al. Human CD8+ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J Infect Dis 212 (2015), 1743–1751.
18. Kirkpatrick, B.D., Durbin, A.P., Pierce, K.K., Carmolli, M.P., Tibery, C.M., Grier, P.L., et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 212 (2015), 702–710.
19. Kirkpatrick, B.D., Whitehead, S.S., Pierce, K.K., Tibery, C.M., Grier, P.L., Hynes, N.A., et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med 8 (2016), 330–336.
20. Grifoni, A., Angelo, M., Sidney, J., Paul, S., Peters, B., de Silva, A.D., et al. Patterns of cellular immunity associated with experimental infection with rDEN2Delta30 (Tonga/74) supports its suitability as a human DENV challenge strain. J Virol, 2017.
21. Rivino, L., Kumaran, E.A., Jovanovic, V., Nadua, K., Teo, E.W., Pang, S.W., et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 87 (2013), 2693–2706.
22. Weiskopf, D., Bangs, D.J., Sidney, J., Kolla, R.V., De Silva, A.D., de Silva, A.M., et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci USA 112 (2015), E4256–E4263.
23. Gil, L., Izquierdo, A., Lazo, L., Valdes, I., Ambala, P., Ochola, L., et al. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys. Virology 456–457 (2014), 70–76.
24. Guy, B., Briand, O., Lang, J., Saville, M., Jackson, N., Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine 33 (2015), 7100–7111.
25. Guzman, M.G., Kouri, G., Valdes, L., Bravo, J., Vazquez, S., Halstead, S.B., Enhanced severity of secondary dengue 2 infections occurring at an interval of 20 compared with 4 years after dengue 1 infection. PAHO J Epidemiol 81 (2002), 223–227.
26. Guzman, M.G., Kouri, G., Valdes, L., Bravo, J., Alvarez, M., Vazquez, S., et al. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol 152 (2000), 793–799.